Patanjali to launch ayurvedic drug for Covid-19, claims cure within 14 days

Balkrishna had earlier this month claimed that an Ayurvedic medicine developed by the company has been able to cure Covid-19 patients within 5-14 days

Patanjali Ayurved
The Patanjali CEO further said that people should practice Yoga, and keep oneself healthy through proper diet to boost the immune system
ANI
2 min read Last Updated : Jun 23 2020 | 7:45 AM IST

Patanjali will launch the ayurvedic medicine for treating Covid-19 at Patanjali Yogpeeth in Haridwar on Tuesday.

"Proud launch of first and foremost evidence-based ayurvedic medicine for #corona contagion, #SWASARI_VATI, #CORONIL, is scheduled for tomorrow at 12 noon from #Patanjali Yogpeeth Haridwar," Acharya Balkrishna, Chief Executive Officer (CEO) of Patanjali, tweeted on Monday.

Balkrishna had earlier this month claimed that an Ayurvedic medicine developed by the company has been able to cure Covid-19 patients within 5-14 days.

"We appointed a team of scientists after Covid-19 outbreak. Firstly, the simulation was done and compounds were identified which can fight the virus and stop its spread in the body. Then, we conducted a clinical case study on hundreds of positive patients and we have got 100 per cent favourable results," Balkrishna said.


"After taking our medicine, COVID patients recovered in 5-14 days and then tested negative. So, we can say the cure for COVID is possible through Ayurveda. We are performing controlled clinical trials only. In the next 4-5 days, evidence and data will be released by us," he added.

The Patanjali CEO further said that people should practice Yoga, and keep oneself healthy through proper diet to boost the immune system.

With an increase of 14,821 new cases and 445 deaths, India's Covid-19 count crossed 4.25 lakh on Monday. The country has reported a total of 4,25,282 cases and 13,699 persons have died.

The Health Ministry said that 9,440 patients have been cured in the last 24 hours and the country's recovery rate has gone up to 55.77 per cent.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccinePatanjaliHealth Ministry

Next Story